Alphabet's record Q4 results show strong revenue growth, particularly in Google Cloud. Click here to read why we now rate ...

The fact that the GLD has performed at par with the broader equity market is a major red flag for equities. Read more to see ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Read here for a discussion on semiconductor industry uncertainties from US-China trade tensions, AI competition, and ...

Innoviz Technologies faces financial challenges and lack of profitability in the competitive automotive industry. Read why I ...

AI capex is ramping up among major hyperscalers as they significantly increase their investments. Read what this means for ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

Global X AIQ ETF is a top buy with strong performance and diverse holdings, outperforming peers LRNZ and THNQ. Click here to ...

Lindt & Sprüngli remains resilient amid rising cocoa prices, with organic revenue up 7.8% in FY 2024. Find out what justifies ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

RTX Corporation reported strong Q4 results with double-digit sales growth across all channels. Read why I have upgraded RTX ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...